Spring 2022, blooming flowers
2022 New Year, New Discoveries: Images of scientists conducting experiments and various lab equipment
Rotator commemorating NCI at Frederick's 50th anniversary: black-and-white images of scientists and staff working at the facility and meeting with other scientists
Winter 2021 rotator: images of snow, icicles, and holly at NCI at Frederick
Science in Frederick rotator: images of devices and scientists performing experiments

By Frank Blanchard, Staff Writer The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.
Platinum Publications are selected from articles by NCI at Frederick scientists published in 42 prestigious science journals. This list represents articles published during the time period shown above, as generated from PubMed. Articles designated as Platinum Highlights are noteworthy articles selected by Dr. Craig Reynolds, associate director, National Cancer Institute, from among the most recently published Platinum Publications.
By Nancy Parrish, Staff Writer The Frederick National Laboratory for Cancer Research (FNLCR) recently formed a partnership with the Pancreatic Cancer Action Network (PanCAN) to award a one-year fellowship to two scientists whose research will help lead to new therapies for pancreatic cancer. The scientists will focus on KRAS, a gene in the RAS family that is mutated in 95 percent of pancreatic cancers, according to the National Cancer Institute (NCI). 
By Nancy Parrish, Staff Writer; photo by Richard Frederickson, Staff Photographer Normal cells have mechanisms to prevent the development of cancer. Among these is a type of tumor suppressor mechanism known as oncogene-induced senescence, or OIS, which halts the uncontrolled growth of cells caused by mutations in oncogenes. The oncogene Ras plays a crucial role in inducing OIS through a specific cascade of proteins, as reported in a recent article in Molecular and Cellular Biology by Jacqueline Salotti, Ph.D., and colleagues in the Eukaryotic Transcriptional Regulation
By Nancy Parrish, Staff Writer; photos by Richard Frederickson, Staff Photographer Approximately 50 college students, professors, and high school teachers from Frederick County Public Schools gathered at Hood College for the second annual National Interagency Confederation for Biological Research (NICBR) Exploring Careers in a Scientific Environment Symposium (NECSES). The Feb. 13 event highlighted the wide range of scientific research as well as the educational and career opportunities available through NICBR partner organizations.

Subscribe to Poster

The subscriber's email address.
CAPTCHA

Dates to Note

Upcoming Holidays

Labor Day
September 2, 2024

Columbus Day
October 14, 2024

Veterans Day
November 11, 2024

Thanksgiving Day
November 28, 2024

Christmas Day
December 25, 2024

New Year's Day
January 1, 2025

Martin Luther King Jr. Day
January 20, 2025

Presidents Day
February 17, 2025